Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c

Tvardi Therapeutics (NASDAQ: TVRD) reported Q2 EPS of ($0.69), $0.01 better than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Tvardi Therapeutics (TVRD) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Nkarta Inc. (NKTX) PT Lowered to $10 at Stifel as Ntrust-1/2 Trial Enrollment Progresses
• Evolv Technology adds 70 customers in Q2, expands bag screening